Evidence map›Paper›PMID 42230676›Full record

ArticleScientific reports2026

Tumor suppressor effects of miR-143 and miR-199 on the K562 myelogenous leukemia cell line by targeting the RNA-binding protein Musashi2.

Liana Lachinani, Rana Iranpour, Mahboobeh Forouzanfar, Mohammad Hossein Nasr-Esfahani, Kianoush Dormiani

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liana Lachinani *Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Rana Iranpour *Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Mahboobeh ForouzanfarDepartment of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Mohammad Hossein Nasr-EsfahaniDepartment of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Kianoush DormianiDepartment of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran. k_dormiani@royaninstitute.org.

Funding

Royan Institute 95000295
6 · The paper itself

Abstract

The RNA-binding protein Musashi2 plays a critical role in normal and malignant hematopoiesis. Aberrant expression of Musashi2 is linked to the inappropriate expression of several miRNAs. In this study, we observed downregulation of miR-143 and miR-199 in CML and AML cell lines. Bioinformatic analysis revealed potential interactions between these miRNAs and Musashi2 mRNA, which were also confirmed by our experimental data. In K562 cells, which showed the strongest negative correlation between Musashi2 and the candidate miRNAs, overexpression of miRNAs led to reduced cell proliferation and invasiveness. Overexpression of miR-143 and miR-199 decreased the mRNA and protein levels of Musashi2 in K562 cells, a CML cell line. MiR-143 exhibited a more significant reduction in cell proliferation and invasion compared to miR-199a. Our results indicate that the overexpression of these tumor suppressor miRNAs and the subsequent downregulation of Musashi2 are responsible for reducing the cancerous properties of malignant myeloid cells, although the potential targeting of other genes by these miRNAs may contribute to these effects. Accordingly, these miRNAs could also be investigated for their effects on the behavior of cancer cells derived from clinical samples of myelogenous leukemias to evaluate their potential roles as new molecular targets in the treatment of this type of cancer.

Indexed as

Genes, Tumor SuppressorLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsNerve Tissue ProteinsRNA-Binding ProteinsCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, LeukemicGene Expression Regulation, NeoplasticHumansK562 CellsMicroRNAsMIRN143 microRNA, humanmirn199 microRNA, humanMSI2 protein, humanNerve Tissue ProteinsRNA-Binding ProteinsmiRNAMSI2Myeloid leukemiaRNA-binding proteinTumor suppressor

Identifiers

PMID42230676
PMCPMC13470451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.